tion. Conclusions: Success of the LAD2 line reflects the demand for a human mast cell line in research, the uniqueness of this cell line, and that it continues to exhibit minimal variation from its original description. We hope that the awareness of the impact of this cell line on mast cell research will encourage others to develop and distribute other similar cell lines with additional characteristics so as to address the limitations of depending on the study of cultured human mast cells from tissues.
Introduction
Mast cells are known to play a major role in innate and acquired immunity. Since 2003, there have been three major cell lines, HMC-1 (Human Mast Cell leukemia-1) [1] , LAD2 (Laboratory of Allergic Diseases 2) [2] and LUVA (Laboratory of University of VirginiA) [3] , available for study of human mast cell biology in lieu of primary mast cell cultures derived from bone marrow, or peripheral or cord blood. The LAD2 mast cell line most closely resembles primary human mast cell cultures due to (1) functional FcεRI receptors and the ability to degranulate to immunologic stimuli, and (2) growth dependence on the presence of stem cell factor (SCF). LAD2 human mast cells have been maintained in our laboratory for use and distribution worldwide following completion of either a NIHapproved Material Transfer Agreement (MTA) or Licensing Agreement (LA) in the case of for profit companies.
To determine whether completed MTAs and LAs represented successful transfer and use of cells and resulted in publications in peer-reviewed journals, we investigated the total number of agreements completed by investigators and companies, their geographic distribution and purpose of use, and publications using LAD2 cells. We also investigated whether the LAD2 cell line had retained its original properties over the past decade. As will be seen, the LAD2 cell line appears to owe its success, evident from its worldwide appeal and publications, to its consistent nature and performance in the laboratory. It is hoped that the research contributions in part dependent on the availability of this cell line will encourage others to develop and distribute similar cell lines using our approach as detailed in this report.
Materials and Methods

Data Collection
Records maintained in our laboratory, the Technology Transfer and Intellectual Property Office (TTIPO) and the Office of Technology Transfer (OTT), were reviewed for numbers and locations of non-profit investigator MTAs, and for-profit company LAs. Peer-reviewed journals and their impact factors were obtained from PubMed.gov by cross-referencing LAD2 and human mast cells. All data was expressed in Excel spreadsheet format.
LAD2 Cell Studies
LAD2 cells were developed as described and maintained in StemPro serum-free media with supplements and rhSCF [2] . Hemidepletions were performed weekly. To examine LAD2 CD surface markers, cells were incubated in 1 × PBS containing 0.1% BSA and 1% milk, followed by staining with directly conjugated antibodies as described [4] . All analyses were performed on at least 10,000 cells. β-Hex release was assayed following crosslinking of FcεRI as described [5] . Briefly, LAD2 cells were incubated overnight with human 100 ng/ml human myeloma IgE (BD PharMingen, San Diego, Calif., USA) biotinylated by the NIAID core facility, followed by crosslinking with 125 ng/ml streptavidin (SigmaAldrich, St. Louis, Mo., USA). β-Hex was reported as % of total cell contents released.
Karyotypic Analysis
Karyotyping of chromosomes was performed on LAD2 cells. To determine the karyotype of LAD2 cells, metaphases were harvested from 5-10 × 10 6 cells that were arrested in metaphase, using colcemid overnight, placed in hypotonic potassium chloride, and fixed in methanol and acetic acid. Analysis using spectral karyotyping and composite karyotyping was performed for studying chromosomal number and aberrations, following nomenclature rules from ISCN, 2009 (http://www.karger.com/Book/Home/244102).
Sequencing of LAD2 KIT cDNA
Total RNA was extracted from 1 × 10 6 LAD2 cells using the RNeasy Plus RNA isolation kit (Qiagen, Germantown, Md., USA) as described [6] . Approximately 1 μg of total RNA was reverse transcribed using the SuperScript III First-Strand synthesis system (Invitrogen, Grand Island, N.Y., USA) with random hexamer primers. The KIT gene was PCR amplified from cDNA using Phusion high-fidelity DNA polymerase (New England BioLabs, Ipswich, Mass., USA). Overlapping KIT PCR amplification products were gel-purified and directly sequenced by Genewiz (Germantown, Md., USA). Sequencing data was analyzed using Sequencher, Version 4.5 (Softgenetics, State College, Pa., USA).
Results
MTA and LA requests are forwarded to either TTIPO or OTT, respectively, for processing and completion prior to the shipping of LAD2 cells. Handling instructions are provided when answering requests. Investigators must have necessary reagents and facilities for cell culture and for cryopreserving cells, a current shipping address and commercial carrier service prior to receiving cells. NIH departmental handling of domestic requests generally requires 2-3 weeks to complete. The process is longer for international requests, depending on import restrictions to the host country. This process has not in general been a problem for investigators, and as shown in figure  1 LAD2 cells have been shipped worldwide, with most shipments going to laboratories within the United States, followed by Great Britain, Japan, Germany and the Netherlands ( fig. 2 a) . North America and Europe share almost equally in the numbers of agreements successfully completed ( fig. 2 b) .
To determine whether research involving LAD2 cells has been cited in journal publications, we surveyed PubMed by cross-referencing LAD2 and human mast cells as well as HMC-1 and LUVA cells. Research using LAD2 cells has been published in journals with impact factors ranging from 1.31 to 13.21. Since 2005, there have been 353 publications referencing HMC-1 cells, 84 publications for LAD2 cells, and 2 publications for LUVA cells. Paper titles and abstracts suggest that research involving LAD2 cells is broad and involves studies of mast cell degranulation, development of new compounds in-hibiting degranulation, receptor identification, examination of cell signaling and studies of genetic markers. In 2011 and 2012 combined, at least 25 journals published papers citing the use of LAD2 cells in research. Research which examined functional FcεRI receptor crosslinking in addition to certain G protein-coupled receptors found on LAD2 but not HMC-1 cells resulted in publications that provided the most advance onto our previous knowledge of the biology of human mast cells, and include the following: inhibition of STAT3 serine 727 phosphorylation in human mast cells leads to impaired FcεRI-mediated proximal and distal signaling, as well as reduced degranulation, consistent with the absence of clinical atopy in autosomal-dominant hyper-IgE syndrome [7] ; CD84 is highly expressed in human mast cells and dampens FcεRI-mediated calcium mobilization and degranulation with release of IL-8 and GM-CSF after its co-crosslinking with FcεRI [8] ; MrgX2 is a novel GPCR on human mast cells for the antibacterial peptide cathelicidin (LL-37) which is involved in innate immunity and promotes inflammation, angiogenesis, wound healing and tumor metastasis [9] ; human β-defensins and LL-37 stimulate the secretion of a novel pruritogenic mediator IL-31 from human mast cells, suggesting a novel mechanism by which skin-derived antimicrobial peptides/proteins may contribute to inflammatory skin reactions [10] , and leukotriene (LT)E 4 , in contrast to LTD 4 , activates peroxisome proliferator-activated receptor-γ and induces prostaglandin D 2 generation which may help to explain how LTE 4 in vivo potentiates airway hyperresponsiveness and induces bronchial eosinophilia [11] . Together, this strongly suggests that researchers, reviewers and journal editorial staff alike have accepted the LAD2 human mast cell line in the study of human mast cell biology. One can speculate that the success investigators have enjoyed publishing with the LAD2 cell line as a research tool is due to the stability and minimal variation from characteristics originally described in 2002. To examine this possibility, LAD2 cells were tested for function, CD surface marker expression and sequencing of the c-kit proto-oncogene for the activating D816 mutation. As shown in figure 3 a, the newest lot of LAD2 cells thawed early in 2013, expanded and kept in culture according to handling instructions, gave consistently high (20-60%) % β-hex release, similar to the release of this cell line in studies performed in 2012 and similar to the original description of the cell line. Flow cytometry studies confirmed not only the presence of FcεRI, CD4, 9, 13, 14, 22, 31, 32, 45, 64, 71, 103, 117, 132, CD184 and CD195 as originally described, but the constitutive expression of activation markers CD63 and 203c (data not shown). Finally, complete sequencing of KIT showed two reported SNPs at amino acid positions aa529 (bp 1674) and aa531 (bp 1680), the presence of the GNNK variation [12] and as S715aa deletion polymorphism. These variations were not known in 2003. As shown in figure 3 b, the major D816V activating mutation which could contribute to the cell line's immortality was not present, consistent with the original 
Discussion
Our NIH laboratory has as its mission to conduct basic research, promote 'bench-to-bedside' research, foster progress in patient care, and to make specific resources available to other laboratories to further their research 
